La angina de pecho estable continúa siendo en la era de la revascularización un problema relevante. Su trascendencia se sustenta en su alta prevalencia (un 2-4% de la población) y en el consumo de recursos sanitarios que origina. Su pronóstico es más favorable que el de los síndromes coronarios agudos, pero origina deterioro de la calidad de vida y frecuentes problemas terapéuticos. La mortalidad anual se encuentra en torno a un 0,5-2,6% y la incidencia de infarto no fatal es del 1-2% al año. Los objetivos del tratamiento de los pacientes con angina estable son: a) mejorar el pronóstico previniendo el infarto de miocardio y la muerte mediante la reducción de la incidencia de eventos trombóticos agudos y el desarrollo de disfunción ventricular izquierda, y b) mejorar los síntomas reduciendo los episodios isquémicos y aumentar la calidad de vida. El tratamiento antianginoso frecuentemente es subóptimo por un bajo grado de adhesión a las guías y por los frecuentes efectos secundarios. Intervenciones destinadas a mejorar la cumplimentación de las guías y nuevos fármacos, como la ivabradina, pueden ayudar a optimizar el tratamiento de los pacientes con angina estable.
Palabras clave
Cardiopatía isquémica
Angina de pecho
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
C. Fernández-Palomeque, J.L. Bardají, M. Concha, J.C. Cordo, J. Cosín, J. Magriñá, et al.
Guías de práctica clínica de la Sociedad Española de Cardiología en la angina estable.
Rev Esp Cardiol, (2000), 53 pp. 967-996
[2.]
Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina), 2002. Disponible en: www.acc.org/clinical/guidelines/stable/stable
[3.]
Fox K, Alonso MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: full text. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. doi:10.1093/eurheartj/ehl002.
[4.]
Grupo de trabajo de Angina de Pecho. Conclusiones del grupo de trabajo de «Angina de Pecho».
Clasificación y tratamiento de la angina de pecho.
Rev Esp Cardiol, (1985), 35 pp. 297-305
[5.]
J. Azpitarte, A. Cabadés, V. López-Merino, M. De los Reyes, J. San José, En representación del Grupo de estudio de Angina de Pecho de la Sección de Cardiopatía Isquémica y Unidades Coronarias de la Sociedad Española de Cardiología: Angina de pecho.
Concepto y clasificación.
Rev Esp Cardiol, (1995), 48 pp. 373-382
[6.]
G.A. Rose, H. Blackburn.
Cardiovascular survey methods.
Monogr Ser World Health Organ, (1968), 56 pp. 1-188
[7.]
D.G. Cook, A.G. Shaper, P.W. MacFarlane.
Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology.
Int J Epidemiol, (1989), 18 pp. 607-613
[8.]
P. Ducimetiere, J.B. Ruidavets, M. Montaye, B. Haas, J. Yarnell.
5 year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.
Int J Epidemiol, (2001), 30 pp. 1057-1062
[9.]
J. Cosín, E. Asín, J. Marrugat, R. Elosúa, F. Arós, M. De los Reyes, On behalf of the PANES study investigators.
Prevalence of angina pectoris in Spain.
Eur J Epidemiol, (1999), 15 pp. 323-330
[10.]
L. López-Bescós, J. Cosín, R. Elosúa, A. Cabadés, M. De los Reyes, F. Arós.
Prevalencia de angina y factores de riesgo cardiovascular en las diferentes comunidades autónomas de España. Estudio PANES.
Rev Esp Cardiol, (1999), 52 pp. 1045-1056
[11.]
R. Masia, A. Pena, J. Marrugat, J. Sala, J. Vila, M. Paresi, The REGICOR investigators, et al.
High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence.
J Epidemiol Commun Health, (1998), 52 pp. 707-715
[12.]
F.C. Lampe, R.W. Morris, P.H. Whincup, M. Walker, S. Ebrahim, A.G. Shaper.
Is the prevalence of coronary heart disease falling in british men?.
Heart, (2001), 86 pp. 499-505
[13.]
E. Sigurdsson, G. Thorgeirsson, H. Sigvaldason, N. Sigfusson.
Prevalence of coronary heart disease in Icelandic men 1968-1986. The Reykjavic Study.
Eur Heart J, (1993), 14 pp. 584-591
[14.]
H. Tunstall-Pedoe, K. Kuulasmaa, M. Mahonen, H. Tolonen, E. Ruokokoski, P. Amouyel.
Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.
Lancet, (1999), 353 pp. 1547-1557
[15.]
C.A. Daly, F. Clemens, J.L. López Sendón, L. Tavazzi, E. Boersma, N. Danchin, et al.
The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologist in Europe: from the Euro Heart Survey of Stable Angina.
Eur Heart J, (2005), 26 pp. 996-1010
[16.]
C.A. Daly, F. Clemens, J.L. López Sendón, L. Tavazzi, E. Boersma, N. Danchin, et al.
The initial management of stable angina in Europe: from the EuroHeart Survey. A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the EuroHeart Survey of Stable Angina.
Eur Heart J, (2005), 26 pp. 1011-1022
[17.]
R. Holubkov, W.K. Laskey, A. Haviland, J.C. Slater, M.G. Bourassa, H. Aslanidou Vlachos, et al.
Angina 1 year after percutaneous coronary intervention: a report from the NHLBI dynamic registry.
Am Heart J, (2002), 144 pp. 826-833
[18.]
R.A. Henderson, S.J. Pocock, T.C. Clayton, R. Knight, K.A.A. Fox, D.G. Julian, et al.
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.
J Am Coll Cardiol, (2003), 42 pp. 1161-1170
[19.]
P.W. Serruys, F. Unger, E. Sousa, A. Jatene, H.J.R.M. Bonnier, J.P.A.M. Schönberger, For the Arterial Revascularization Therapies Study Group, et al.
Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.
N Engl J Med, (2001), 344 pp. 1117-1124
[20.]
N. Rehnqvist, P. Hjemdahl, E. Billing, I. Bjorkander, S.V. Eriksson, L. Forslund, et al.
Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS).
Eur Heart J, (1996), 17 pp. 76-81
[21.]
H.J. Dargie, I. Ford, K.M. Fox, On behalf of the TIBET study group.
Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina.
Eur Heart J, (1996), 17 pp. 104-112
[22.]
C.J. Pepine, E.M. Handberg, R.M. Cooper-DeHoff, R.G. Marks, P. Kowey, F.H. Messerli, et al.
A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
JAMA, (2003), 290 pp. 2805-2816
[23.]
C. Brunelli, R. Cristofani, A. L’Abbate.
Long-term survival en medically treated patients with ischaemic heart disease and prognostic importante of clinical and electrocardiographic data (the Italian CNR Mulicentre Study OD1).
Eur Heart J, (1989), 10 pp. 292-303
[24.]
M. Heras, H. Bueno, A. Bardaji, A. Fernández-Ortiz, H. Martí, J. Marrugat.
Magnitude and consequences of undertreatment in highrisk patients with non-ST-segment elevation acute coronary syndromes. Insights from the DESCARTES Registry.
Heart, (2006), 92 pp. 1571-1576
[25.]
F.C. Wiest, C.L. Bryson, M. Burman, M.B. McDonell, J.G. Henikoff, S. Fhin.
Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting.
Am J Med, (2004), 117 pp. 234-241
[26.]
J.A. Spertus, T. Dewhurst, C.M. Dougherty, P. Nichol.
Testing the effectiveness of converting patients to long-acting antianginal medications: The Quality of Life in Angina Research Trial (QUART).
Am Heart J, (2001), 141 pp. 550-558
[27.]
J.S. Borer, K. Fox, P. Jaillon, G. Lerebours.
Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
Circulation, (2003), 107 pp. 817-823
[28.]
J.C. Tardif, I. Ford, M. Tendera, M.G. Bourassa, K. Fox.
Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina.
Eur Heart J, (2005), 26 pp. 2529-2536
[29.]
W. Ruzyllo, I. Ford, M. Tendera.
Antianginal and antiischemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherpy in patients with chronic stable angina [resumen].
Eur Heart J, (2004), 25 pp. 878
[30.]
IONA Study Group.
Effect of nicorandil on coronary events in patients with stable angina: the impact of Nicorandil in Angina (IONA) randomised trial.
Lancet, (2002), 359 pp. 1269-1275
[31.]
M. Marzilli, W.W. Klein.
Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials.
Coron Artery Dis, (2003), 14 pp. 171-179
[32.]
E.I. Chazov, V.K. Lepakchin, E.A. Zharova, S.B. Fitilev, A.M. Levin, E.G. Rumiantzeva, et al.
Trimetazidine in angina combination therapy —the TCT study: trimetazidine versus conventional treatment in patients with stable angina pectoris ina a randomized, placebo-controlled, multicenter study.
Am J Ther, (2005), 12 pp. 35-42
[33.]
B.R. Chaitman, S.L. Skettino, J.O. Parker, P. Hanley, K. Meluzin, J. Kuch, et al.
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
J Am Coll Cardiol, (2004), 43 pp. 1375-1382
[34.]
B.R. Chaitman, C.J. Pepine, J.O. Parker, J. Skopal, G. Chumakova, J. Kuch, et al.
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
JAMA, (2004), 291 pp. 309-316
Copyright ©
2007. Sociedad Española de Cardiología